诺为泰（Novotech）：2023鼻咽癌：全球临床试验概况报告（中译版）（16页）.pdf

1、novotech-Global Clinical Trial LandscapeJULY 25,2023Nasopharyngeal Carcinoma Didyouknow?Nasopharyngeal carcinoma(NPC)is the primary cancer that develops in the nasopharynx from its epithelium.It is commonly found in Asia and Africa and is often characterized by undiferentiated features.Non-keratiniz

2、ing undiferentiated carcinoma comprises 50%of all NPC.NPC afected over 130,000 people and is the 23rd most common cancer worldwide in 2020.NPC is more common in males,with a male-to-female ratio ranging from 2-3 to 1.Asia accounted for majority of the global NPC cases in 2020.NPC is endemic in South

3、ern China and Southeast Asia,with a high incidence rate,linked to environmental factors like smoking,alcohol,and nitrosamines,as well as genetics and EBV infection.NPC is rare in the US and Europe,comprising around 6%of global cases in 2020.APAC contributed 60%of NPC trials,led by Mainland China and

4、 Australia.The US and Europe conducted 30%of NPC trials,with France and Spain in the lead.APAC showed the shortest trial duration and fastest enrolment rate in comparison to the US and Europe.60%30%Asia Pacific showed positive growth while the US declined,and Europe remained stable in the past five

5、years.The leading biopharma companies that received funding for NPC are Tessa Therapeutics Ltd.and Elpiscience Biopharma Ltd.Antibodies are the most common molecule type under development across multiple phases for NPC,indicating their significance in potential treatments for this cancer type.The An

6、tibody-Drug Conjugate(ADC)in Phase I/II development exhibits potential for treating,NPC,particularly in metastatic or relapsed cases.NASOPHARYNGEAL CARCINOMA(NPC)GLOBAL CLINICAL TRIAL LANDSCAPEThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may